To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer
Clinical trial NCT04671303 · COMPLETED
Trial details
- NCT number
- NCT04671303
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-01
- Primary completion
- 2023-06-30
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.